Jolijn R van Leeuwen

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 4

Top Topics

Chronic Lymphocytic Leukemia

Diffuse Large B Cell Lymphoma

Top Venues

Biologics : targets & therapy

Clinical kidney journal

This page only lists publications with an associated author ORCID identifier.

Publications

Jolijn R van Leeuwen, Sophia Hafemann, Paul van der Boog, Diane van der Woude, Ton J Rabelink, Y K Onno Teng
The impact of reclassification by the 2022 ACR/EULAR classification criteria on risk factors for relapse in patients with ANCA-associated vasculitis. Clinical kidney journal 16 (12) (2023)
Jolijn R van Leeuwen, Tamara Popov, Achim Obergfell, Ton J Rabelink, Y K Onno Teng
Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis. Biologics : targets & therapy 17 (2023)
Jolijn R van Leeuwen, Tamara Popov, Achim Obergfell, Ton J Rabelink, Y K Onno Teng
Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis. Biologics : targets & therapy 17 (2023)
Ebru Dirikgil, Jolijn R van Leeuwen, Obbo W Bredewold, Argho Ray, Jacqueline T Jonker, Darius Soonawala, Hilde H F Remmelts, Bastiaan van Dam, Willem Jan Bos, Cees van Kooten, Joris Rotmans, Ton Rabelink, Y K Onno Teng
ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial. BMJ open 12 (9) (2022)